Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome – a single center experience (preliminary study)
Journal Title: Progress in Health Sciences - Year 2014, Vol 4, Issue 1
Abstract
Introduction: Mycophenolate mofetil (MMF) is used in treatment of idiopathic nephrotic syndrome in children (INS). Purpose: To evaluate clinical results of MMF treatment in steroid-dependent (SD) and steroid-resistant (SR) nephrotic syndrome. Materials and methods: A retrospective analysis of 26 patients (19 boys, 7 girls) with SDINS and SRINS treated with MMF during the years 2003–2013 was made. The remission length of INS and number of relapses per year before the introduction of MMF and after 12 months was calculated. An analysis of the side effects was made. Results: The median age of INS diagnosis was 26.5 months (IQRs 24-36 months). Nineteen of the patients (73%) suffered from SDINS whereas the remaining 7 (27%) had SRINS. Twenty three (88.5%) patients underwent renal biopsy: minimal change disease (MCD) in 69.6% (n=16), focal segmental glomerulosclerosis (FSGS) in 17.4% (n=4), membranoproliferative glomerulonephritis (MPGN) in 8.7% (n=2) and mesangial cell proliferation in one case. The median MMF dosage was 956.0 mg/m2/24h (IQRs 768.1-1059.7 mg/m2/24h). Eleven patients (42.3%) were taking MMF together with cyclosporine A (CsA). In patients suffering from SDINS, there was a trend to lower the recurrence rate during MMF treatment [2.0/year (IQRs 0.25-2.0 per year) vs 2.0/year (IQRs 1.0-2.75 per year), p=0.09]. Remission without proteinuria was significantly longer in patients treated with MMF; remission median was 8.5 month (IQRs 6.25-11.0 month) vs 4.5 month (IQRs 4.0-7.5 month), (p=0.014), similarly the average length of remission without corticosteroids was 6.0 months (IQRs 0.25-8.5 months) vs 3.0 months (IQRs 0.0-7.25) months (p=0.028). In children SRINS, 4/7 children MMF treatment was clinically ineffective. Side effects of the treatment were: leucopenia (n =10), hyperbilirubinemia (n = 3), gastrointestinal disorders (n = 1) and anemia (n = 1). Conclusion: This study confirmed the efficacy of the treatment with MMF in SDINR in comparison with previously used drugs, with a small number of side effects.
Authors and Affiliations
D Tomczyk, A Jander, J Mihailescu, M Tkaczyk
Keywords
Related Articles
- EP ID EP75173
- DOI -
- Views 91
- Downloads 0
The oncoprotein HBXIP – its functions and roles in oncogenesis
Nowadays, Hepatitis B X interacting protein (HBXIP) is an object of scientists’ interest worldwide. It is a protein with significant involvement in the development of malignant tumors like breast or ovarian cancer. One o...
Quality of life of osteoarthritis patients in the aspect of analgesic treatment
<b>Introduction:</b> Osteoarthritis an inflammatory process in the synovial membrane. These changes cause pain and joint deformities. Pharmacists can assess patients’ quality of life, which can be a good criterion for as...
Differing attitudes for various population groups towards homeless people
Introduction: People who are homeless are most often unable to acquire and maintain regular, safe, secure, and adequate housing, or they lack a “fixed, regular, and adequate night-time residence”. Purpose: To assess the...
Skin changes in the neck and selenium content in patients with thyroid diseases
Purpose: Occurrence of skin changes, in the form of discolouration on neck and in form of a so-called ”thyroid shadow”, was observed in patients with: Hashimoto’s disease, Graves´ disease, struma nodosa euthyrotica or hy...
Evaluation of renal function in primary care
Evaluation of renal function is one of the primary tools used in treatment and monitoring kidney injury such as acute kidney injury (AKI) or chronic kidney disease (CKD) in Primary Care patients. Accompanying chronic dis...